56 research outputs found
Sex differences in dementia risk and risk factors: Individualāparticipant data analysis using 21 cohorts across six continents from the COSMIC consortium
Introduction: Sex differences in dementia risk, and risk factor (RF) associations with dementia, remain uncertain across diverse ethnoāregional groups. Methods: A total of 29,850 participants (58% women) from 21 cohorts across six continents were included in an individual participant data metaāanalysis. Sexāspecific hazard ratios (HRs), and womenātoāmen ratio of hazard ratios (RHRs) for associations between RFs and allācause dementia were derived from mixedāeffect Cox models. Results: Incident dementia occurred in 2089 (66% women) participants over 4.6 years (median). Women had higher dementia risk (HR, 1.12 [1.02, 1.23]) than men, particularly in lowā and lowerāmiddleāincome economies. Associations between longer education and former alcohol use with dementia risk (RHR, 1.01 [1.00, 1.03] per year, and 0.55 [0.38, 0.79], respectively) were stronger for men than women; otherwise, there were no discernible sex differences in other RFs. Discussion: Dementia risk was higher in women than men, with possible variations by countryālevel income settings, but most RFs appear to work similarly in women and men
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; pā=ā0.40). There was no significant effect of DMF on any secondary outcome
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study
Ristola M. on tyƶryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jƤsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; pā=ā0.40). There was no significant effect of DMF on any secondary outcome
The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. In this review, we present the clinical spectrum and pathogenesis of syndromes caused by Aspergillus in COPD namely invasive aspergillosis (IA), community-acquired Aspergillus pneumonia, chronic pulmonary Aspergillosis and Aspergillus sensitisation. Some of these entities are clearly linked to COPD, while others may coexist, but are less clearly liked directly to COPD. We discuss current uncertainties as these pertain to IA in COPD cohorts and explore areas for future research in this field
Space-time clustering of childhood leukaemia in Greece: Evidence supporting a viral aetiology
The method introduced by Knox for evaluation of space-time clustering
has been applied to 872 cases of childhood (0-14 year old) leukaemia
diagnosed in Greece over the 10 year period 1980-89. Greek towns are
characterised by substantial population mixing due to internal
migration, whereas there is relative isolation in mountainous rural
areas. Predetermined space (5 km) and time (1 year) limits were used on
the basis of previous reports in order to define the clustering cell.
There is highly significant evidence for clustering of childhood
leukaemia in Greece as a whole, the observed number of pairs that are
close in both space and time exceeding the expected number by 5.2%
(P=0.004). The excess is particularly evident for leukaemia cases in 0
to 4-year-old children, among whom the observed number of pairs that are
close in both space acid time exceeded the expected number by 9.4%
(P=0.004). There is no evidence of space-time clustering for leukaemia
cases older than 5 years. The overall pattern is descriptively similar
in urban and semiurban areas and is especially marked for acute
lymphoblastic leukaemia at the childhood peak ages (2-4 years) with an
excess of 19% (P=0.0006). In the rural population there is evidence for
clustering of cases belonging to older and broader age groups, a
phenomenon compatible a with a delay in the development of herd immunity
against putative infectious aetiological agents. The findings of the
present study provide support For the hypothesis that a substantial
proportion of cases of childhood leukaemia may arise as a rare sequel to
exposure to an agent or agents, most probably viral in nature
Development of a composite index of quality of life and well-being (QoL/WB) for cancer patients and survivors in the context of the ONCORELIEF project
Background/rationale or Objectives/purpose: Healthcare professionals (HCPs) and industry need to be better aware of the unmet needs, expectations and preferences of cancer patients, survivors (CP&S) and their informal carers. The objective of this study, under the ONCORELIEF Project, was to develop a composite index of QoL/WB to be included in the decision making about risks and benefits of new health interventions for CP&S, in which the different scores will provide a set of metrics to allow HCPs and stakeholders to identify and monitor different levels of cancer patientās QoL/WB, across their treatment and survivorship process
A digital guardian angel app based on a patient- centered AI system to enhancing cancer patient's wellbeing and health status improvement following treatment
ONCORELIEF aims to validate in real-world settings the development of a patient-centered AI system which inputs, analyses and integrates big datasets from the biopsychosocial and environmental dimensions of patients with cancer, to improve post-treatment health status, increase the wellbeing and QoL, and assist the follow-up care of cancer patients. The AI system will generate an ongoing Wellbeing Index to capture the quality of life and well-being of cancer patients. A smart digital assistant (Guardian Angel) for smartphones will provide personalized support to cancer patients in post-treatment activities and tasks and suggest actions regarding the patientsā overall health-status and wellbeing index
Aggregation of childhood leukemia in geographic areas of Greece
A total of 872 children aged up to 14 years, who were diagnosed with leukemia in Greece during the decade 1980-89, were allocated by place of residence to the 601 administrative districts of the country. Evaluation of spatial clustering was done using the Potthoff-Whittinghill method, which validly assesses heterogeneity of leukemia risk among districts with variable expected numbers of cases. There was highly significant evidence for spatial clustering occurring particularly among children living in urban and, to a lesser extent, semi-urban areas. The evidence was stronger for children younger than 10 years old, applied also to children in different five-year age groups, and persisted when cases of acute lymphoblastic leukemia were analyzed separately These findings provide support to the hypothesis that localized environmental exposures could contribute to the etiology of childhood leukemia, but they cannot distinguish between exposures of physical or chemical nature, nor can they exclude socially conditioned patterns of exposure to infectious agents
- ā¦